Molecular Oncology

Analysis of BRCA1 and BRCA2 Genes for Screening Against Breast, Ovarian, and Prostate Cancer Risk

Cancer is a serious disease caused by the mutation of certain genes. These mutations cause cells to grow uncontrollably and abnormally. Breast cancer is the most common type of cancer in women worldwide, while ovarian cancer is the fifth most common cancer in Europe. Approximately 10% of breast cancers and 15% of ovarian cancers are hereditary. Additionally, between 5% and 15% of prostate cancers are also hereditary.

Mutations in BRCA1 and BRCA2 Genes Are the Most Significant Risk Factors for Breast, Ovarian, and Prostate Cancer

nherited mutations in the BRCA1 and BRCA2 genes are the most common cause of hereditary breast cancer and increase the risk of developing other cancers in both men and women. Harmful mutations in BRCA genes can lead to early-onset breast or ovarian cancer, even before the age of 30. First-degree relatives of a person carrying a BRCA gene mutation have a significantly higher risk of developing cancer.

Each child of a parent carrying a BRCA gene mutation has a 50% chance of inheriting the mutation. The presence of a family member diagnosed with breast cancer before age 40 increases the risk for the rest of the family. About 50% of women with BRCA1 or BRCA2 mutations have no family history of breast or ovarian cancer and may be unaware of the mutations that cause cancer.

As previously mentioned, BRCA genes are also linked to hereditary prostate cancer. Specifically, BRCA2 is the gene most frequently associated with an increased risk of this cancer. Some studies suggest that, in men under the age of 65, mutations in the BRCA1 gene double the risk of prostate cancer, while mutations in BRCA2 increase the risk by as much as seven times.

Genechron offers preventive, quick and safe screening with clear and fast results

Survival rates for breast, ovarian, and prostate cancer increase significantly when detected at an early stage, when treatment options are more effective. The lack of signs and symptoms in the early stages often leads to a late diagnosis, which is associated with low survival rates. Current standard procedures can only detect changes already present in the tissue, indicating that cancer progression has already begun. Early detection and accurate identification of BRCA1 and BRCA2 gene mutations can make a crucial difference.

 

Genechron: servizi di genetica - oncologia molecolare

BRCA1 and BRCA2 gene screening can save lives by identifying mutation carriers early, allowing preventive treatments to be implemented at the most effective stage.

The test offered by Genechron provides precise and reliable results from BRCA1 and BRCA2 gene analysis within approximately one month from the receipt of the sample in the laboratory.

 

Our test is:

  • Easy: The DNA sample needed for the analysis is collected via a simple blood draw.​
  • Accurate: Comprehensive sequencing of BRCA1 and BRCA2 genes. Detection of all pathogenic mutations.
  • Precocious: Both young women and men can be eligible for this screening test. Early detection allows for more effective preventive action for personal well-being.
  • Reliable: The test is highly sensitive and provides accurate results.

    Genechron S.r.l. offers a service that also includes the complete sequencing of the coding regions and the mutional analysis of the following genes: TP53, RET, MSH2/MLH1, CDKN2A. Furthermore, the analysis of the V617F mutation of the JAK2 gene can also be requested.

Three panels:

Ovarian and Breast Cancer or Prostate Cancer Panel
Extended Germline Panel for Women
Extended Germline Panel for Men

From Research to Advanced Health Care Diagnostics

CONTACT US WITHOUT COMMITMENT WITH THE METHOD YOU PREFER

+39.06.5036729

info@genechron.com

WhatsApp

+39.388.9233366

Registered office and laboratory Via Giunio Antonio Resti 63 - 00143 Roma

Share This